Abstract Development of novel therapies for central nervous system (CNS) disorders has
experienced a high failure rate in clinical trials owing to unsatisfactory efficacy and adverse …

Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized
pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and …

Extensive studies indicate that mitochondria dysfunction is pivotal for Alzheimer's disease
(AD) pathogenesis; while cumulative evidence suggests that increased mitochondrial stress …

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by
resting tremor, bradykinesia, rigidity, and postural instability that also includes non-motor …

Alzheimer's Disease (AD) represents a complex interplay of neurological pathways and
molecular mechanisms, with significant impacts on patients' lives. This review synthesizes …

A monoamine oxidase B (MAO-B) selective positron emission tomography (PET) tracer
[11C]-deuterium-l-deprenyl holds promise for imaging reactive astrogliosis in …

Background Peripheral glial fibrillary acidic protein (GFAP) and neurofilament light chain
(NfL) are sensitive markers of neuroinflammation and neuronal damage. Previous studies …

Ageing is a key factor in the development of cognitive decline and dementia, an increasing
and challenging problem of the modern world. The most commonly diagnosed cognitive …

Oligoarginine peptides, known mostly for their cell-penetrating properties, are also inhibitors
of the nicotinic acetylcholine receptors (nAChRs). Since octa-arginine (R8) inhibits α9α10 …